Aimmune Therapeutics (AIMT) Reports Licensing of Exclusive Worldwide Rights to Xencor (XNCR) XmAb7195 for Development of Next-Generation Food Allergy Treatments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Aimmune Therapeutics (AIMT) PT Raised to $34 at Credit Suisse
February 4, 2020 5:47 AM ESTCredit Suisse analyst Evan Seigerman raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $34.00 (from $30.00) while maintaining a Neutral rating.... More
Aimmune Therapeutics (AIMT) PT Raised to $81 at Wedbush
February 3, 2020 12:53 PM ESTWedbush analyst Liana Moussatos raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $81.00 (from $79.00) while maintaining a Outperform rating.
... MorePre-Open Movers 02/03: (INSM) (AIMT) (GILD) Higher; (NKTR) (CHKP) (NOC) Lower (more...)
February 3, 2020 9:23 AM ESTToday's Pre-Open Movers
Insmed Incorporated (Nasdaq: INSM) 47.2% HIGHER; announced positive top-line results from its global, randomized, double-blind placebo-controlled Phase 2 WILLOW study evaluating the efficacy, safety, and pharmacokinetics of INS1007 administered once daily in adults with non-cystic fibrosis bronchiectasis (NCFBE). INS1007 is a novel, oral, selective, reversible inhibitor of dipeptidyl peptidase 1 (DPP1).
CTI BioPharma Corp. (Nasdaq: CTIC) 17.7% HIGHER; today announced its intent to raise $60 million through a fully backstopped rights offering. Under the terms of the rights... More
Aimmune Therapeutics (AIMT) PT Raised to $70 at Stifel
February 3, 2020 7:03 AM ESTStifel analyst Derek Archilia raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $70.00 (from $62.00) while maintaining a Hold rating.... More
Aimmune Therapeutics (AIMT) Confirms FDA Approves its PALFORZIA as First Treatment for Peanut Allergy
February 3, 2020 6:58 AM ESTAimmune Therapeutics, Inc. (Nasdaq: AIMT) announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA is the first approved treatment for patients with peanut allergy. It is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial dose escalation may be administered to patients aged 4 through 17 years. Up-dosing and maintenance may be continued in patients 4 years of age and... More
Aimmune Therapeutics (AIMT) PT Raised to $44 at JMP Securities
February 3, 2020 4:40 AM ESTJMP Securities analyst Liisa Bayko raised the price target on Aimmune Therapeutics (NASDAQ: AIMT) to $44.00 (from $40.00) while maintaining a Market Outperform rating.... More
